Astellas, Boehringer Say Co-Marketed Blood-Pressure Drug Safe
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma and its co-marketer in Japan defended their Micardis (telmisartan) blood-pressure drug against a claim it increases the risk of cancer